Importance of Clinical Trials Participation

Only about 5% of women with a gynecologic cancer participate in the dozens of clinical trials in gynecologic cancers. The predominant hope for improving on the treatment options for women diagnosed with a gynecologic cancer is through the conduct of clinical trials.

The Foundation for Women’s Cancer actively works with the Gynecologic Oncology Group (GOG) to encourage women to participate in clinical trials. Clinical trials are a crucial step in finding new and improved ways to improve treatment for women diagnosed with a gynecologic cancer.

Three examples of the important advances in the care of women as a result of clinical trials include:

  • Chemotherapy added to radiation improve cure rate in locally advanced cervical cancer (GOG 120, 109)
  • Platinum based chemotherapy plus paclitaxel is superior to platinum based chemotherapy plus cyclophosphamide (GOG 111)
  • IP therapy improves survival in subsets of women with newly diagnosed advanced ovarian cancer (GOG 172)

The patients that participated in the phase III clinical trials that led to these discoveries were among the first to benefit from these scientific advancements.

Spotlight

SGO, ASCCP Clarify Recommendations of Primary HPV Testing for Cervical Cancer Screening. Read the release.

Awareness

We’re pleased to partner with the Dana Farber Cancer Institute to promote their recent webchat on cervical cancer treatment - watch now!

Research

The Foundation’s research award winners will be notified in January. Thank you to all who sent in their applications.

Education

The next Gynecologic Cancer Survivors Course is February 7-8 in Anchorage, Alaska. For more information, click here.